Prevention of RSV disease in babies starts at HUS hospitals
RSV (respiratory syncytial virus) is the most common cause of respiratory infections leading to infant hospitalization. HUS offers an antibody developed against the RS virus called nirsevimab to infants and children who are at risk of severe RSV infection.
The aim of nirsevimab is to prevent the majority of severe illnesses and infant hospitalizations caused by RSV. Immunization with nirsevimab is voluntary and free of charge for families.
Nirsevimab is offered to all children born after August 1, 2024. HUS will offer nirsevimab to newborns in all its maternity hospitals from October 23, 2024. Children under the age of one year at risk for severe disease will be offered nirsevimab at HUS New Children's Hospital, Jorvi Hospital, and Hyvinkää Hospital from November 4, 2024, until the end of November.
The City of Helsinki and the wellbeing services counties of Uusimaa are responsible for administering nirsevimab according to their guidelines to healthy children born between August 1 – October 22, 2024
Nirsevimab is effective in preventing RSV infections
A long-acting antibody called nirsevimab is used to prevent RSV infections. It is administered as a single intramuscular injection. Nirsevimab is safe to administer even to newborns, and it provides efficient protection against RSV for the entire winter epidemic.
The product is very safe. It has been in use in several countries during the winter 2023–2024, where it prevented 80–90% of hospitalizations caused by RSV.
Keywords
Contacts
Director Jari Petäjä, p. 050 428 6630, jari.petaja@hus.fi
HUS Children and adolecents
Links
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Gips räcker vid frakturer på mediala humerusepikondylen vid armbågsleden hos barn9.9.2025 09:55:56 EEST | Pressmeddelande
I en nyligen publicerad studie framgick det att gipsning som behandling vid frakturer på mediala humerusepikondylen hos barn är en lika effektiv behandlingsform som operation. De resultat som man nu fått stöder gipsbehandling som primär behandlingsform och behandlingen kan förenhetligas på riksnivå.
Kipsi riittää lasten kyynärnivelen koukistajalisäkkeen murtumissa9.9.2025 09:55:56 EEST | Tiedote
Juuri julkaistussa tutkimuksessa selvisi, että lasten kyynärnivelen koukistajalisäkkeen murtumien hoidossa kipsaus on yhtä tehokas hoitomuoto kuin leikkaus. Nyt saadut tulokset tukevat kipsihoidon käyttöä ensisijaisena hoitomuotona, ja hoitoa voidaan yhtenäistää kansallisesti.
Den nyaste ekonomiska prognosen för hela 2025: HUS är på väg att uppnå sina ekonomiska mål för 20258.9.2025 12:09:48 EEST | Pressmeddelande
HUS-sammanslutningens styrelse behandlade på sitt möte verksamheten och ekonomin i januari–juli samt den nyaste årsprognosen för hela 2025. HUS-sammanslutningens operativa resultat beräknas uppvisa ett överskott på 0,1 miljoner euro. Sammanslutningens styrelse fastställde också investeringsplanen och investeringsprogrammet för de kommande åren.
Koko vuoden 2025 uusin talousennuste: HUS pääsemässä vuonna 2025 taloudellisiin tavoitteisiinsa8.9.2025 12:09:48 EEST | Tiedote
HUSin yhtymähallitus käsitteli kokouksessaan tammi–heinäkuun taloutta sekä uusinta koko vuoden 2025 vuosiennustetta. HUS-yhtymän operatiivisen tuloksen ennustetaan päätyvän 0,1 miljoonaa euroa ylijäämäiseksi. Yhtymähallitus vahvisti myös tulevien vuosien investointisuunnitelman ja -ohjelman.
Förebyggande av RS-virusinfektion hos spädbarn inleds på HUS sjukhus3.9.2025 14:17:24 EEST | Pressmeddelande
RS-virus (respiratory syncytial virus, RSV) är den vanligaste orsaken till luftvägsinfektioner som kräver sjukhusvård hos små barn. HUS erbjuder en antikropp som utvecklats mot RS-virus, det vill säga nirsevimab åt nyfödda och barn under ett år som hör till riskgrupperna.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom